CA2827160A1 - Aptameres se liant a l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme produits therapeutiques des troubles hemostatiques - Google Patents

Aptameres se liant a l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme produits therapeutiques des troubles hemostatiques Download PDF

Info

Publication number
CA2827160A1
CA2827160A1 CA2827160A CA2827160A CA2827160A1 CA 2827160 A1 CA2827160 A1 CA 2827160A1 CA 2827160 A CA2827160 A CA 2827160A CA 2827160 A CA2827160 A CA 2827160A CA 2827160 A1 CA2827160 A1 CA 2827160A1
Authority
CA
Canada
Prior art keywords
aptamer
tfpi
amino acids
seq
aptamers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2827160A
Other languages
English (en)
Inventor
Robert Schaub
Kathleen Mcginness
Jennifer Nelson
Ryan Genga
Emily Waters
Jeffrey Kurz
John Diener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxalta GmbH
Baxter International Inc
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/026,165 external-priority patent/US8598327B2/en
Application filed by Baxter Healthcare SA, Baxalta GmbH, Baxter International Inc, Baxalta Inc filed Critical Baxter Healthcare SA
Publication of CA2827160A1 publication Critical patent/CA2827160A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2827160A 2011-02-11 2012-02-13 Aptameres se liant a l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme produits therapeutiques des troubles hemostatiques Abandoned CA2827160A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/026,165 2011-02-11
US13/026,165 US8598327B2 (en) 2009-08-18 2011-02-11 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
PCT/US2012/024916 WO2012109675A1 (fr) 2011-02-11 2012-02-13 Aptamères se liant à l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme produits thérapeutiques des troubles hémostatiques

Publications (1)

Publication Number Publication Date
CA2827160A1 true CA2827160A1 (fr) 2012-08-16

Family

ID=45771912

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827160A Abandoned CA2827160A1 (fr) 2011-02-11 2012-02-13 Aptameres se liant a l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme produits therapeutiques des troubles hemostatiques

Country Status (5)

Country Link
EP (1) EP2673364A1 (fr)
JP (1) JP6002691B2 (fr)
AU (1) AU2012214148A1 (fr)
CA (1) CA2827160A1 (fr)
WO (1) WO2012109675A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009331570C1 (en) 2008-12-22 2024-04-18 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
EA032189B9 (ru) 2010-03-01 2019-09-30 БАЙЕР ХЕЛЬСКЕР ЛЛСи Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
WO2013142153A2 (fr) * 2012-03-22 2013-09-26 Baxter International Inc. Aptamères pour l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme agents thérapeutiques contre un trouble hémorragique
KR101969402B1 (ko) * 2016-10-27 2019-04-16 대한민국 물사출 분쇄기의 거치장치
CN111411164B (zh) * 2020-05-26 2022-11-01 中国检验检疫科学研究院 利用数字pcr检测番茄溃疡病菌的方法及其使用的成套试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1039935A4 (fr) 1997-02-28 2005-04-27 Univ Iowa Res Found UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1009413B1 (fr) 1997-09-05 2007-02-14 The Regents Of The University Of California Utilisation d'oligonucleotides immunostimulants pour la prevention ou le traitment de l'asthme
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
EP1919499A2 (fr) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation de l'activite du facteur tissulaire par la proteine s et inhibiteur de la voie du facteur tissulaire
US8466108B2 (en) * 2008-12-19 2013-06-18 Baxter International Inc. TFPI inhibitors and methods of use
FR2942232B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre
MX2012002133A (es) * 2009-08-18 2013-02-15 Baxter Healthcare Sa Aptameros para inhibidor de trayectoria de factor de tejido y su uso como terapeuticos para trastorno de sangrado.

Also Published As

Publication number Publication date
AU2012214148A1 (en) 2013-08-29
JP6002691B2 (ja) 2016-10-05
JP2014507147A (ja) 2014-03-27
WO2012109675A1 (fr) 2012-08-16
EP2673364A1 (fr) 2013-12-18

Similar Documents

Publication Publication Date Title
EP2467167B1 (fr) Aptamères dirigés contre un inhibiteur de voie de facteur tissulaire et leur utilisation comme agents thérapeutiques contre des troubles du saignement
US8461318B2 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeutics
AU2009200036B2 (en) Modulators of pharmacological agents
DK1991275T3 (en) Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
US7998939B2 (en) Aptamers that bind thrombin with high affinity
CA2827160A1 (fr) Aptameres se liant a l'inhibiteur de la voie du facteur tissulaire et leur utilisation comme produits therapeutiques des troubles hemostatiques
AU2022202115A1 (en) Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
AU2016204713B2 (en) Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
AU2012244176B8 (en) Modulators of pharmacological agents
AU2012244176B2 (en) Modulators of pharmacological agents

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170215